INTRODUCTION
T he recommendations for the management of hypertension are enshrined in guidelines written by expert groups appointed by national and regional authorities around the world [1] [2] [3] [4] [5] . Some are appointed by health authorities and others by professional medical bodies such as societies of hypertension. These guidelines tend to be updated every 3-5 years and often lag well behind current trends reflecting the most recent evidence from large scale randomized trials, observational studies or meta-analyses. Indeed many studies, published in the last few years, have challenged well entrenched practice, including the use of certain drug classes such as b blockers or diuretics [6] [7] [8] . They have also challenged the accepted thresholds for initiating blood pressure (BP)-lowering treatment and the BP targets for this treatment, in both uncomplicated and high-risk patients groups with various grades of hypertension [9] [10] [11] [12] [13] .
The Forum of the International Society of Hypertension (ISH) brings together national and regional societies of hypertension, leagues against hypertension and councils 
METHODS
This is a cross-sectional survey of national and regional societies affiliated with the ISH. In December 2011, 84 national and six regional societies from 77 countries were invited to participate in the survey using a formal questionnaire. The questionnaire surveyed current use of national, regional and international guidelines, current practice in BP measurement, current recommendations on lifestyle measures, preferred BP-lowering drugs, preferred combinations of drugs, and BP thresholds and targets (see Text Document, Supplemental Digital Content 1, which is the questionnaire used for the survey).
Statistical analysis
Data were recorded as number of societies in the affirmation for each item and/or percentage positive out of all responding societies. Mean values and ranges were also shown for BP thresholds and targets. Subgroup analysis was conducted according to levels of affluence defined according to the World Bank definitions [14, 15] (high-income, upper-middle-income, and combined lower-middle and low-income countries) and trends in percentage across subgroups were evaluated using a logistic regression model. Results were also analysed according to regions [Asia (Bangladesh, China, India, Japan, Philippines, South Korea, Taiwan and Vietnam), Middle East and North Africa [Iran, Lebanon, Libya, Turkey], Europe (Bosnia and Herzegovina, Bulgaria, Italy, Lithuania, Netherlands, Romania, Russia, Serbia, Sweden, Switzerland, and the United Kingdom of Great Britain and Northern Ireland) and Latin America (Argentina, Brazil, Venezuela and the Latin American Society)] and were compared using the x 2 test. P value less than 0.05 was considered statistically significant. All analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, North Carolina, USA).
RESULTS
Thirty-one responses were received between January and June 2012 covering all continents and including nine societies from high-income countries, 17 from uppermiddle-income countries and five from lower-middle or low-income countries as defined by the World Bank [14, 15] Approximately, two-thirds reported use of mercury, aneroid and semi-automatic sphygmomanometers and half reported use of ambulatory BP monitoring (ABPM) ( Table 1) . However, the great majority (27 countries) indicated that decision-making was based on clinic BP. This was supplemented by home BP and ABPM in about half (Table 1) .
There was much variation in recommendations for lifestyle measures, with 31, 27 and 26 nations recommending physical exercise, dietary salt restriction and weight reduction programs, respectively, with much smaller numbers for other dietary programs, for alcohol moderation, for smoking cessation or for stress control programs ( Fig. 1) . Almost all societies reported extensive use of the four major drug classes for uncomplicated patients with hypertension -angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), calcium channel blockers (CCB) and diuretics but 12 of 31 did not recommend b blockers (Fig. 2 ). CCB and diuretics were heavily favoured for use in the elderly, whereas b blockers were not used at all in this group (Fig. 2) . Inhibitors of the renin-angiotensin system (RAS) were clearly preferred for patients with diabetes, with chronic kidney disease or with the metabolic syndrome, whereas b blockers were universally recommended in patients with coronary heart disease ( Fig. 2) . Renin inhibitors and a blockers were only recommended by three and two societies, respectively, for use in uncomplicated patients with hypertension, whereas a blockers were also recommended for use in patients with urinary tract problems. The majority of nations favoured the combination of RAS inhibitors with either CCB (27/31) or with diuretics (22/31) for uncomplicated patients, but a strong majority preferred the combination of CCB with RAS inhibitors for patients with type 2 diabetes ( Table 2) . Only three nations reported continuing use of the old favourite combinationb blockers with diuretics. Although 27/31 nations favoured the use of drug combinations to initiate treatment there was considerable variation in recommendations for the use of fixed-dose (single pill) combinations.
The majority of national societies (28/31) retained the threshold of 140/90 mmHg for initiating drug therapy in uncomplicated hypertension, but only half (18/31) retained this threshold for elderly patients, whereas many preferred a higher threshold of 150/90 mmHg or higher for this group (11/31). There was considerable variation in the threshold preferred for initiating treatment in high-risk groups, such as those with coronary disease, stroke or type 2 diabetes (Table 3) . Although many maintained the previously preferred threshold of 130/80 mmHg, many moved to more conservative thresholds such as 140/90 mmHg or 135/85 mmHg (Table 3 ). There was also some variation in the preferred targets for BP lowering. Whereas the targets of less than 140/90 mmHg was largely retained for uncomplicated patients with hypertension, and that of less than 130/80 mmHg was still preferred by many for patients with type 2 diabetes, there was a clear move to more conservative targets for patients with coronary disease and those with stroke (Table 3) .
Analyses according to levels of affluence did not reveal significant differences except for use of ABPM (eight of nine in high-income, seven of 17 in upper-middle-income and one of five in lower-middle and low-income countries, P ¼ 0.02 for trend) and recommendations on alcohol moderation (seven of nine, seven of 17 and one of five, respectively, P ¼ 0.04 for trend) and on use of CCB for obese patients (two of nine, nine of 17 and four of five, respectively, P ¼ 0.04 for trend). There were also no significant differences between regions except for the use of national guidelines (seven of eight in Asia, zero of five in Middle East and North Africa, eight of 11 in Europe and three of four in Latin America, P ¼ 0.01), use of diuretics for uncomplicated hypertension (seven of eight, two of five, 11 of 11 and three of four, respectively, P ¼ 0.03), use of CCB for coronary heart disease (seven of eight, zero of five, four of 11 and three of four, P ¼ 0.01) and use of combination therapy of CCB with diuretic for uncomplicated hypertension (four of eight, zero of five, one of 11 and zero of four, P ¼ 0.04).
DISCUSSION
There was a remarkable degree of consistency across 31 affiliated societies that responded to this ISH survey on the management of hypertension. This was true both across regions and across variations in income levels.
All nations recommended lifestyle measures for the management of hypertension, but salt restriction, physical exercise and weight reduction were used by the majority, whereas other behavioural modalities such as moderation in alcohol intake, smoking cessation and stress control were used less frequently, even though most are recommended by the major international guidelines [1] [2] [3] [4] [5] .
With regards to drug treatment, it is clear that b blockers are no longer regarded as first-line drugs across the world (Fig. 2) . Indeed, they are virtually not recommended for elderly patient, or those with diabetes, renal disease, stroke Frequency out of 31 responding societies (%) or the metabolic syndrome. These changes seem to be preceded by revision of the British recommendations in 2006 [16] and are in part driven by recent meta-analyses which suggested that b blockers are less effective in preventing cardiovascular disease, particularly in older patients [6] [7] [8] . Their one undisputed role is for patients with coronary disease where they were recommended by 29 of 31 societies. On the contrary, diuretics are still used by the vast majority for uncomplicated and for elderly patients, although they appear to be avoided in high-risk groups such as those with diabetes, renal disease and coronary disease (Fig. 2) . Inhibitors of the RAS, both ACEI and ARB, are uniformly preferred for patients with diabetes or with renal disease, and used extensively across all other groups except the elderly (Fig. 2) . Combination treatment is also uniformly favoured in principle. The most common preferences are for inhibitors of the RAS in combination with either CCB (especially in type 2 diabetes) or with diuretics, clearly demonstrating the influence of large randomized trials such as ACCOMPLISH [17] , ADVANCE [18] and PROGRESS [19] . While most societies supported the use of combinations to initiate treatment, there was greater variation in attitudes and recommendations for the place of single pill or fixed-dose combinations. Despite the consistency of support for the use of combination therapy around the world, it is ironic that one of the biggest dilemmas in our field continues to be the great gap between evidence and practice, with very low levels of achievement of recommended BP targets worldwide [20] [21] [22] [23] [24] [25] . It is possible, of course, that the recent debates about recommended BP target levels will prolong and exacerbate this unsatisfactory level of BP control at global level [9] [10] [11] [12] [13] .
In most nations, thresholds for initiation of BP-lowering treatment vary according to presence or absence of cardiovascular risk factors and/or target organ diseases. There are also variations in BP targets across patients groups with different risk profiles (e.g. diabetes, coronary heart disease and stroke). It is for these reasons that most of the current guidelines for management of hypertension recommend therapeutic approaches based on absolute risk of cardiovascular disease as well as on BP levels [1, [3] [4] [5] . For highrisk patients with coronary heart disease, stroke or type 2 diabetes, only half retained the BP threshold and target of approximately 130/80 mmHg. The trend towards more conservative thresholds and targets may reflect the recent publication of observational data from large-scale studies [9] [10] [11] [12] [13] as reflected in the reappraisal of European guidelines on hypertension management [26] . Of particular interest was the consistency of findings across countries with very different levels of income. The exceptions were in the use of ABPM, and the recommendations for moderation in alcohol intake, both of which were much less common in low resource settings, and in the use of CCB for obese patients, which was much less common in affluent nations. Although the limited use of ABPM in low resource settings is readily understood, the reasons for the other two findings are less obvious. Consistent findings were also observed across different geographical regions. The exceptions were low use of national guidelines and use of diuretic for uncomplicated hypertension in Middle East and North Africa, and high use of CCB for coronary heart disease and combination of CCB with diuretic for uncomplicated hypertension in Asia. Use of national guidelines is likely to be associated with their availability and high use of CCB for coronary disease in Asia may be related to higher prevalence of vasospastic angina in the region [27] . For the other two findings, however, the reasons for the difference are not clear.
This report has a number of strengths. It was compiled using data provided by senior office bearers within expert societies, from a wide range of regions and resource settings. It also has some limitations including the fact that in most instances it reflects the impressions formed by senior office bearers, rather than facts based on hard national data. Furthermore, the response rate was disappointing with only 31 out of 90 societies responding, and there were very few responses from low-income countries.
In conclusion, this ISH survey drew on the goodwill of its affiliated societies and the responses indicate broad consistency in the management of hypertension across countries differing widely in culture, in economic circumstances and in geographical location. There was a clear tendency towards more conservative BP thresholds and targets for BP lowering therapy. The use of b blockers has become much more limited, being mainly reserved for patients with coronary heart disease. Drugs from the other four major classes (ACEI, ARB, CCB and diuretics) appear to be recommended in line with the available evidence. There is a clear need for simple and practical guidelines suitable for use in low-income setting across the world, particularly countries that lack the resources to develop their own national recommendations.
